

**Notice of References Cited**

 Application/Control No.  
 09/709,170

 Applicant(s)/Patent Under  
 Reexamination  
 WARRELL ET AL.

 Examiner  
 Terra Gibbs

 Art Unit  
 1635

Page 1 of 3

**U.S. PATENT DOCUMENTS**

*	Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
A	US-6,214,986 B1	06-1999	Bennett et al.	536/24.5
B	US-			
C	US-			
D	US-			
E	US-			
F	US-			
G	US-			
H	US-			
I	US-			
J	US-			
K	US-			
L	US-			
M	US-			

**FOREIGN PATENT DOCUMENTS**

*	Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
N					
O					
P					
Q					
R					
S					
T					

**NON-PATENT DOCUMENTS**

Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages

*	U	Fl Raynaud et al. Journal of Pharmacology and Experimental Therapeutics, "Pharmacokinetics of G3139, a Phosphorothioate Oligodeoxynucleotide... Intravenous Administration or Continuous Subcutaneous Infusion to Mice," Dec. 1996, Vol. 281, No. 1, pp. 420-427
	V	DE Lopes de Menezes et al., Clinical Cancer Res., "Molecular and Pharmacokinetic Properties Associated with the Therapeutics of Bcl-2...Rhee and Liposomal Doxorubicin," Jul. 2000, Vol. 6, pp. 2891-2902.
	W	H Miyake et al., Journal of the Natl. Cancer Institute, "Chemosensitization and Delayed Androgen-Independent Recurrence...Antisense Bcl-2 Oligodeoxynucleotides," Jan. 2000, Vol. 92, No. 1, pp. 34-41.
	X	FE Cotter et al., Biochimica et Biophysica Acta 1489, "Human Bcl-s antisense therapy for lymphomas," 1999, pp. 97-106.

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)

Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

## Notice of References Cited

Application/Control No.  
09/709,170

Applicant(s)/Patent Under  
Reexamination  
WARRELL ET AL.

Examiner  
Terra Gibbs

Art Unit  
1635

Page 2 of 3

### U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

### FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

### NON-PATENT DOCUMENTS

Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages

*		
	U	A Webb et al., The Lancet, "BCL-2 antisense therapy in patients with non-Hodgkin lymphoma," Apr. 1997, Vol. 349, pp. 1137-1141.
	V	JS Waters et al., Journal of Clinical Oncology, "Phase I Clinical and Pharmacokinetic Study of Bcl-2 Antisense Oligonucleotide Therapy in Patients with Non-Hodgkin's Lymphoma," May 2000, Vol. 18, No. 9, pp. 1812-1823.
	W	W Tong et al., American Society of Clinical Oncology, "Phase I/II Dose-Escalating Trial of bcl-2 Antisense (G3139) Treatment by 14-Day Continuous...Solid Tumor Malignancies," 1999, Abstract.
	X	BJansen et al., American Society of Clinical Oncology, "Phase I-II Study with Dacarbazine and BCL-2 Antisense Oligonucleotide G3139(GENTA)...Advanced Malignant Melanoma," 1999, Abstract.

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)  
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

**Notice of References Cited**

 Application/Control No.  
 09/709,170

 Applicant(s)/Patent Under  
 Reexamination  
 WARRELL ET AL.

 Examiner  
 Terra Gibbs

 Art Unit  
 1635

Page 3 of 3

**U.S. PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

**FOREIGN PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

**NON-PATENT DOCUMENTS**

*		Include as applicable. Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	B Jansen et al., The Lancet, "Chemosensitisation of malignant melanoma by BCLa antisense therapy," Nov. 2000, Vol. 356, pp. 1728-1733.
	V	
	W	
	X	

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)  
 Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.